06:37:42 EST Fri 06 Dec 2024
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save

News for U:PLSE from 2023-12-07 to 2024-12-06 - 27 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-10-31 14:25U:PLSENews ReleasePulse Biosciences Announces Positive Clinical Data Presented at the American Thyroid Association
2024-10-30 16:05U:PLSENews ReleasePulse Biosciences Reports Business Updates and Third Quarter 2024 Financial Results
2024-10-30 16:02U:PLSENews ReleasePulse Biosciences Announces Appointment of David Kenigsberg, M.D. as Chief Medical Officer of Electrophysiology
2024-10-21 08:00U:PLSENews ReleasePulse Biosciences Schedules Third Quarter 2024 Financial Results Conference Call for October 30, 2024
2024-08-12 16:05U:PLSENews ReleasePulse Biosciences Reports Business Updates and Preliminary Second Quarter 2024 Financial Results
2024-08-12 16:01U:PLSENews ReleasePulse Biosciences, Inc. Appoints Paul LaViolette to Its Board of Directors
2024-08-08 08:00U:PLSENews ReleasePulse Biosciences, Inc. Announces Successful Treatment of Patients in First-in-Human Study with its Nano-PFA Cardiac Surgery System
2024-08-01 16:05U:PLSENews ReleasePulse Biosciences, Inc. Announces Participation in Upcoming Investor Conferences
2024-07-29 16:05U:PLSENews ReleasePulse Biosciences Schedules Second Quarter 2024 Financial Results Conference Call for August 12, 2024
2024-07-08 08:00U:PLSENews ReleasePulse Biosciences, Inc. Announces Receipt of FDA Breakthrough Device Designation for CellFX(TM) nsPFA Cardiac Surgery System for the Treatment of Atrial Fibrillation
2024-07-03 14:44U:PLSENews ReleasePulse Biosciences, Inc. Announces the Closing of its Rights Offering
2024-06-28 08:00U:PLSENews ReleasePulse Biosciences, Inc. Announces Preliminary Results for its Rights Offering
2024-05-20 16:05U:PLSENews ReleasePulse Biosciences Announces Updated Timing of Rights Offering for Up to $60,000,000
2024-05-16 08:00U:PLSENews ReleasePulse Biosciences' CellFX Nanosecond Pulsed Field Ablation (nsPFA(TM)) Technology to be Featured in Several Presentations at The Heart Rhythm Society 2024 Annual Meeting
2024-05-14 16:05U:PLSENews ReleasePulse Biosciences Enhances Executive Leadership Team
2024-05-09 08:00U:PLSENews ReleasePulse Biosciences Announces First U.S. Procedure with the CellFX nsPFA Percutaneous Electrode System
2024-05-07 16:05U:PLSENews ReleasePulse Biosciences Reports Business Updates and First Quarter 2024 Financial Results
2024-05-02 08:00U:PLSENews ReleasePulse Biosciences Announces Timing of Rights Offering for Up to $60,000,000
2024-04-24 16:05U:PLSENews ReleasePulse Biosciences Schedules First Quarter 2024 Financial Results Conference Call for May 7, 2024
2024-03-28 16:12U:PLSENews ReleasePulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2023 Financial Results
2024-03-28 16:10U:PLSENews ReleasePulse Biosciences Announces Plans to Initiate a Rights Offering
2024-03-14 16:05U:PLSENews ReleasePulse Biosciences Schedules Fourth Quarter & Full Year 2023 Financial Results Conference Call for March 28, 2024
2024-03-08 13:17U:PLSENews ReleasePulse Biosciences Announces FDA 510(k) Clearance for its CellFX(TM) nsPFA(TM) Percutaneous Electrode System
2024-02-14 08:00U:PLSENews ReleasePulse Biosciences Announces Positive 60-Day Follow-Up Evaluations for Initial Patients treated in the CellFX ‚ ® nsPFA ¢ „ ¢ 360 ‚ ° Cardiac Catheter First-in-Human Feasibility Study
2024-01-31 08:00U:PLSENews ReleasePulse Biosciences Announces Preliminary Findings from its CellFX nsPFA 360 Cardiac Catheter First-In-Human Feasibility Study to be Featured in Podium Presentation at the AF Symposium
2024-01-02 08:00U:PLSENews ReleasePulse Biosciences Files 510(k) Submission with U.S. FDA for its CellFX ‚ ® nsPFA ¢ „ ¢ Cardiac Clamp
2023-12-20 08:00U:PLSENews ReleasePulse Biosciences Announces First-in-Human Procedures with its Novel CellFX ¢ „ ¢ Nanosecond Pulsed Field Ablation (nsPFA ¢ „ ¢) Cardiac Catheter